Switch theme
Sign up to access all valuation multiples
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
2008
3.5K+
LTM Revenue $296M
LTM EBITDA -$134M
$4.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RemeGen has a last 12-month revenue (LTM) of $296M and a last 12-month EBITDA of -$134M.
In the most recent fiscal year, RemeGen achieved revenue of $218M and an EBITDA of -$140M.
RemeGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RemeGen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $296M | XXX | $218M | XXX | XXX | XXX |
| Gross Profit | $240M | XXX | $175M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$134M | XXX | -$140M | XXX | XXX | XXX |
| EBITDA Margin | -45% | XXX | -64% | XXX | XXX | XXX |
| EBIT | -$181M | XXX | -$175M | XXX | XXX | XXX |
| EBIT Margin | -61% | XXX | -80% | XXX | XXX | XXX |
| Net Profit | -$188M | XXX | -$187M | XXX | XXX | XXX |
| Net Margin | -63% | XXX | -86% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $231M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, RemeGen's stock price is HKD 58 (or $7).
RemeGen has current market cap of HKD 32.8B (or $4.2B), and EV of HKD 34.9B (or $4.5B).
See RemeGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5B | $4.2B | XXX | XXX | XXX | XXX | $-0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, RemeGen has market cap of $4.2B and EV of $4.5B.
RemeGen's trades at 20.4x EV/Revenue multiple, and -31.9x EV/EBITDA.
Equity research analysts estimate RemeGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RemeGen has a P/E ratio of -24.3x.
See valuation multiples for RemeGen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV/Revenue | 16.4x | XXX | 20.4x | XXX | XXX | XXX |
| EV/EBITDA | -36.1x | XXX | -31.9x | XXX | XXX | XXX |
| EV/EBIT | -26.8x | XXX | -25.5x | XXX | XXX | XXX |
| EV/Gross Profit | 20.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -24.3x | XXX | -22.4x | XXX | XXX | XXX |
| EV/FCF | -28.3x | XXX | -24.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRemeGen's last 12 month revenue growth is 39%
RemeGen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
RemeGen's rule of 40 is -77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RemeGen's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for RemeGen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Margin | -45% | XXX | -64% | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -77% | XXX | -25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 160% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RemeGen acquired XXX companies to date.
Last acquisition by RemeGen was XXXXXXXX, XXXXX XXXXX XXXXXX . RemeGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was RemeGen founded? | RemeGen was founded in 2008. |
| Where is RemeGen headquartered? | RemeGen is headquartered in Hong Kong. |
| How many employees does RemeGen have? | As of today, RemeGen has 3.5K+ employees. |
| Is RemeGen publicy listed? | Yes, RemeGen is a public company listed on HKG. |
| What is the stock symbol of RemeGen? | RemeGen trades under 09995 ticker. |
| When did RemeGen go public? | RemeGen went public in 2020. |
| Who are competitors of RemeGen? | Similar companies to RemeGen include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of RemeGen? | RemeGen's current market cap is $4.2B |
| What is the current revenue of RemeGen? | RemeGen's last 12 months revenue is $296M. |
| What is the current revenue growth of RemeGen? | RemeGen revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of RemeGen? | Current revenue multiple of RemeGen is 16.4x. |
| Is RemeGen profitable? | Yes, RemeGen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of RemeGen? | RemeGen's last 12 months EBITDA is -$134M. |
| What is RemeGen's EBITDA margin? | RemeGen's last 12 months EBITDA margin is -45%. |
| What is the current EV/EBITDA multiple of RemeGen? | Current EBITDA multiple of RemeGen is -36.1x. |
| What is the current FCF of RemeGen? | RemeGen's last 12 months FCF is -$171M. |
| What is RemeGen's FCF margin? | RemeGen's last 12 months FCF margin is -58%. |
| What is the current EV/FCF multiple of RemeGen? | Current FCF multiple of RemeGen is -28.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
